Five-year study results of the NuVasive Simplify Cervical Disc were presented at the 38th Annual Meeting of the North American Spine Society

“Having clinically sound, long-term data for the Simplify Cervical Disc validates the promising clinical data we saw Simplify have after two years,” said Kyle Malone, senior vice president, Scientific Affairs, Globus Medical. “We will continue to innovate within the cervical spine segment and provide industry-leading procedural solutions that are clinically designed to deliver better patient outcomes.”

The five-year Simplify Cervical Disc study* found:

• Simplify Cervical Disc was statistically superior to the ACDF Control in terms of overall composite success at five years,
• Statistically significant postoperative improvements in the Neck Disability Index (NDI) and visual analogue scale (VAS) (combined neck and arm pain) found at two years were maintained over five years, with the Simplify Cervical Disc group experiencing significantly lower NDI and had VAS scores at five years. years compared to the ACDF control,
• Mean disc height and flexion/extension range of motion increased postoperatively in the Simplify Disc group and remained above preoperative levels throughout follow-up, and
• No device errors were reported in the Simplify Disc group.

Dr. Pierce Nunley of the Spine Institute of Louisiana expressed enthusiasm about the durability of the positive results seen after 24 months. He stated: “I am eager to see the continued success of these results after 60 months. This study further reinforces that Simplify is an excellent motion-saving solution with lasting clinical benefits over ACDF.”

*Data on file.

Simplify Cervical Disc is not yet available in all countries. Please refer to the Simplify Disc directions for use and patient labeling for important product information, including but not limited to indications, contraindications, warnings, precautions, risks and possible side effects. The instructions for use and patient labeling can be found here.

About Globus Medical, Inc.
Globus Medical is committed to delivering innovative technologies and leading clinical support to help surgeons and healthcare providers deliver better care around the world. The company offers one of the most comprehensive offerings of musculoskeletal solutions and assistive technologies to impact the continuum of care, now including NuVasive’s procedurally integrated portfolio. The company’s employees are relentlessly focused on advancing patient care. For more information, visit www.globusmedical.com/uniting.

Safe Harbor Statements
All statements in this press release, other than statements of historical fact, are forward-looking statements and can be identified by the use of words such as “believe,” “may,” “could,” “could,” “will.” aim”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that could affect our business and operations and could cause actual results to differ materially from those projected. These risks and uncertainties include, but are not limited to, the risks and costs associated with the integration of, and the ability of Globus Medical and NuVasive to successfully integrate their businesses and realize expected synergies, health epidemics, pandemics and similar outbreaks . including the COVID-19 pandemic, factors affecting our quarterly results, our ability to manage our growth, our ability to maintain our profitability, demand for our products, our ability to compete successfully (including but not limited to our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and implement successful business strategies our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to protect our intellectual property, our success in defending legal proceedings against us, trends in the medical device industry , general economic conditions and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, please refer to the disclosure in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” and in our Forms 10-Q, Forms 8-K and other filings with the Securities and Exchange Commission. These documents are available at www.sec.gov. Moreover, we operate in a changing environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business, or the extent to which any factor, or combination of factors , could cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors that arise or come to our attention after the date hereof.

Contact person for investors:
Brian Kears
610-930-1800
investors@globusmedical.com

Media contact:
Melanie Ordoñez
858-722-3899
media@globusmedical.com